PADMANEE SHARMA to Young Adult
This is a "connection" page, showing publications PADMANEE SHARMA has written about Young Adult.
Connection Strength
0.131
-
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
Score: 0.053
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.011
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.011
-
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 10 01; 36(28):2836-2844.
Score: 0.011
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.010
-
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
Score: 0.010
-
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
Score: 0.010
-
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05; 373(19):1803-13.
Score: 0.009
-
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
Score: 0.008